PT  - JOURNAL ARTICLE
AU  - Mosley, Mary
ED  - Modest, Dominik
TI  - Impact of First-Line Therapy on Selection of Second-Line Therapy in FIRE-3 Trial
DP  - 2014 Nov 01
TA  - MD Conference Express
PG  - 16--16
VI  - 14
IP  - 22
4099  - http://mdc.sagepub.com/content/14/22/16.short
4100  - http://mdc.sagepub.com/content/14/22/16.full
AB  - The influence of the drug combination used for first-line therapy on the selection and duration of the second-line therapy in patients with metastatic colorectal cancer (mCRC) was the objective of a post hoc analysis in the ongoing 5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer trial [FIRE-3]. This article discusses the effect of first-line therapy on overall survival (OS) and the selection of subsequent treatment, and the effect of second-line therapy on OS [Modest D et al. Ann Oncol. 2014 (abstr O-0018)].